Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Current Liabilities for 7 consecutive years, with $96.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 46.76% to $96.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.9 million through Dec 2025, down 46.76% year-over-year, with the annual reading at $96.9 million for FY2025, 46.76% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $96.9 million at Beam Therapeutics, down from $182.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $238.9 million in Q3 2022, with the low at $96.9 million in Q4 2025.
  • Average Total Current Liabilities over 5 years is $180.1 million, with a median of $184.9 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities soared 230.46% in 2021, then plummeted 46.76% in 2025.
  • Over 5 years, Total Current Liabilities stood at $213.4 million in 2021, then increased by 4.76% to $223.6 million in 2022, then decreased by 8.06% to $205.6 million in 2023, then dropped by 11.43% to $182.1 million in 2024, then tumbled by 46.76% to $96.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $96.9 million, $182.6 million, and $174.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.